Edition:
United States

Capricor Therapeutics Inc (CAPR.OQ)

CAPR.OQ on NASDAQ Stock Exchange Capital Market

0.41USD
20 Feb 2019
Change (% chg)

-- (--)
Prev Close
$0.41
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
42,629
52-wk High
$1.95
52-wk Low
$0.31

Chart for

About

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the... (more)

Overall

Beta: -2.65
Market Cap(Mil.): $67.20
Shares Outstanding(Mil.): 23.50
Dividend: --
Yield (%): --

Financials

  CAPR.OQ Industry Sector
P/E (TTM): -- 69.44 33.70
EPS (TTM): -0.83 -- --
ROI: -645.84 8.92 14.45
ROE: -- 10.08 15.96

U.S. drug developer Capricor places Duchenne drug trial on hold

Capricor Therapeutics Inc said on Wednesday it had put on hold a clinical trial of its drug to treat Duchenne muscular dystrophy (DMD), a muscle-wasting disorder, citing a safety review.

Dec 26 2018

UPDATE 1-U.S. drug developer Capricor places Duchenne drug trial on hold

Dec 26 Capricor Therapeutics Inc said on Wednesday it had put on hold a clinical trial of its drug to treat Duchenne muscular dystrophy (DMD), a muscle-wasting disorder, citing a safety review.

Dec 26 2018

Capricor places Duchenne drug trial on hold

Dec 26 Capricor Therapeutics Inc said on Wednesday it had put on hold a clinical trial of its drug to treat Duchenne muscular dystrophy, a muscle-wasting disorder.

Dec 26 2018

Earnings vs. Estimates